Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1639, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-1550, 2016. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet Lond Engl, vol.389, pp.255-265, 2017. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1833, 2016. ,
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, vol.378, issue.22, pp.2078-2092, 2018. ,
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, vol.378, issue.24, pp.2288-2301, 2018. ,
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, vol.379, issue.24, pp.2342-2350, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02284390
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, N Engl J Med, vol.378, issue.21, pp.1976-1986, 2018. ,
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med, vol.379, issue.23, pp.2220-2229, 2018. ,
Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV nonsmall cell lung cancer treated by nivolumab, Oncoimmunology, vol.8, issue.5, p.1580128, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02342305
,
Clinical predictive factors for 3-months disease control with immune checkpoint inhibitors in patients with non-small cell lung cancer ,
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev, vol.45, pp.30-37, 2016. ,
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell, vol.33, issue.4, pp.570-580, 2018. ,
Modulation of cancer immunotherapy efficacy by gut microbiota, Discov Med, vol.27, issue.147, pp.93-100, 2019. ,
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis, Br J Cancer, vol.105, issue.1, pp.93-103, 2011. ,
Inflammation and cancer: back to Virchow?, Lancet Lond Engl, vol.357, issue.9255, pp.539-545, 2001. ,
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers, Br J Cancer, vol.117, issue.7, pp.913-920, 2017. ,
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer, Br J Cancer, vol.107, issue.4, pp.695-699, 2012. ,
Baseline neutrophils and derived neutrophil-tolymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.4, pp.732-738, 2016. ,
Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies, Ann Oncol, issue.suppl_6, p.27, 2016. ,
Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients, vol.6, 2016. ,
Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer, JAMA Oncol, vol.4, issue.3, pp.351-357, 2018. ,
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors, The Oncologist, 2019. ,
Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine, Semin Cancer Biol, vol.35, pp.53-61, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01195547
Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients, Br J Cancer, vol.116, issue.3, pp.344-348, 2017. ,
Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma, CPT Pharmacomet Syst Pharmacol, vol.7, issue.1, pp.42-50, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01624423
Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients, Oncotarget, vol.8, issue.29, pp.47161-47166, 2017. ,
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy, Cancer Res, vol.76, issue.17, pp.4931-4940, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01336779
Immunologically effective dose: a practical model for immuno-radiotherapy, Oncotarget, vol.9, issue.61, pp.31812-31819, 2018. ,
Modélisation mathématique de la cinétique du PSA appliquée à la détection précoce du cancer de la prostate, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol, vol.24, issue.13, p.787, 2014. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, issue.2, pp.228-247, 2009. ,
, The R Project for Statistical Computing, 2019.
Building Predictive Models in R Using the caret Package, J Stat Softw, vol.28, issue.1, pp.1-26, 2008. ,
Regression Models and Life-Tables, J R Stat Soc Ser B Methodol, vol.34, issue.2, pp.187-202, 1972. ,
Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors, Stat Med, vol.15, issue.4, pp.361-387, 1996. ,
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC, Cancer Treat Rev, vol.65, pp.65-77, 2018. ,
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma, Clin Lung Cancer, vol.19, issue.4, pp.421-430, 2018. ,
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.26, issue.7, pp.1139-1145, 2017. ,
Current views on tumor mutational burden in patients with nonsmall cell lung cancer treated by immune checkpoint inhibitors, J Thorac Dis, vol.11, issue.1, pp.71-80, 2018. ,
Signatures of mutational processes in human cancer, Nature, vol.500, issue.7463, pp.415-421, 2013. ,
Mutational heterogeneity in cancer and the search for new cancer genes, Nature, vol.499, issue.7457, pp.214-218, 2013. ,
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, issue.7, pp.633-641, 2018. ,
1295OBlood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK), Ann Oncol, vol.28, issue.suppl_5, 2019. ,
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC), J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.14, issue.6, pp.1095-1101, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02104417
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann Oncol Off J Eur Soc Med Oncol, 2019. ,
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities, Cancer Discov, vol.5, issue.8, pp.860-877, 2015. ,
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma, Cancer Discov, vol.8, issue.7, pp.822-835, 2018. ,
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics, Clin Cancer Res Off J Am Assoc Cancer Res, vol.24, issue.14, pp.3292-3298, 2018. ,
Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma, Oncotarget, vol.8, issue.23, pp.38056-38060, 2017. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.2, pp.123-135, 2015. ,
Big Data and medicine: a big deal, J Intern Med, vol.283, issue.5, pp.418-429, 2018. ,
Machine learning models in breast cancer survival prediction. Technol Health Care Off J, Eur Soc Eng Med, vol.24, issue.1, pp.31-42, 2016. ,
Lung Cancer Survival Prediction via Machine Learning Regression, Classification, and Statistical Techniques, Proc IEEE Int Symp Signal Process Inf Technol IEEE Int Symp Signal Process Inf Technol, vol.2018, pp.632-637, 2018. ,
A radiomics approach to assess tumourinfiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, vol.19, issue.9, pp.1180-1191, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01958243
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1639, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-1550, 2016. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet Lond Engl, vol.389, pp.255-265, 2017. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1833, 2016. ,
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, vol.378, issue.22, pp.2078-2092, 2018. ,
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, vol.378, issue.24, pp.2288-2301, 2018. ,
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, vol.379, issue.24, pp.2342-2350, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02284390
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, N Engl J Med, vol.378, issue.21, pp.1976-1986, 2018. ,
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med, vol.379, issue.23, pp.2220-2229, 2018. ,
Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV nonsmall cell lung cancer treated by nivolumab, Oncoimmunology, vol.8, issue.5, p.1580128, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02342305
,
Clinical predictive factors for 3-months disease control with immune checkpoint inhibitors in patients with non-small cell lung cancer ,
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev, vol.45, pp.30-37, 2016. ,
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell, vol.33, issue.4, pp.570-580, 2018. ,
Modulation of cancer immunotherapy efficacy by gut microbiota, Discov Med, vol.27, issue.147, pp.93-100, 2019. ,
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis, Br J Cancer, vol.105, issue.1, pp.93-103, 2011. ,
Inflammation and cancer: back to Virchow?, Lancet Lond Engl, vol.357, issue.9255, pp.539-545, 2001. ,
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers, Br J Cancer, vol.117, issue.7, pp.913-920, 2017. ,
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer, Br J Cancer, vol.107, issue.4, pp.695-699, 2012. ,
Baseline neutrophils and derived neutrophilto-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.4, pp.732-738, 2016. ,
Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies, Ann Oncol, vol.27, issue.suppl_6, 2019. ,
Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients, vol.6, 2016. ,
Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer, JAMA Oncol, vol.4, issue.3, pp.351-357, 2018. ,
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors, The Oncologist, 2019. ,
Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine, Semin Cancer Biol, vol.35, pp.53-61, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01195547
Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients, Br J Cancer, vol.116, issue.3, pp.344-348, 2017. ,
Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma, CPT Pharmacomet Syst Pharmacol, vol.7, issue.1, pp.42-50, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01624423
Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients, Oncotarget, vol.8, issue.29, pp.47161-47166, 2017. ,
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy, Cancer Res, vol.76, issue.17, pp.4931-4940, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01336779
Immunologically effective dose: a practical model for immuno-radiotherapy, Oncotarget, vol.9, issue.61, pp.31812-31819, 2018. ,
Modélisation mathématique de la cinétique du PSA appliquée à la détection précoce du cancer de la prostate, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol, vol.24, issue.13, p.787, 2014. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 32. R: The R Project for Statistical Computing, vol.45, pp.228-247, 2009. ,
Building Predictive Models in R Using the caret Package, J Stat Softw, vol.28, issue.1, pp.1-26, 2008. ,
Regression Models and Life-Tables, J R Stat Soc Ser B Methodol, vol.34, issue.2, pp.187-202, 1972. ,
Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors, Stat Med, vol.15, issue.4, pp.361-387, 1996. ,
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC, Cancer Treat Rev, vol.65, pp.65-77, 2018. ,
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma, Clin Lung Cancer, vol.19, issue.4, pp.421-430, 2018. ,
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.26, issue.7, pp.1139-1145, 2017. ,
Current views on tumor mutational burden in patients with nonsmall cell lung cancer treated by immune checkpoint inhibitors, J Thorac Dis, vol.11, issue.1, pp.71-80, 2018. ,
Signatures of mutational processes in human cancer, Nature, vol.500, issue.7463, pp.415-421, 2013. ,
Mutational heterogeneity in cancer and the search for new cancer genes, Nature, vol.499, issue.7457, pp.214-218, 2013. ,
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, issue.7, pp.633-641, 2018. ,
1295OBlood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK), Ann Oncol, vol.28, issue.suppl_5, 2019. ,
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC), J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.14, issue.6, pp.1095-1101, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02104417
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann Oncol Off J Eur Soc Med Oncol, 2019. ,
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities, Cancer Discov, vol.5, issue.8, pp.860-877, 2015. ,
, STK11/LKB1 Mutations, p.1
, Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma, Cancer Discov, vol.8, issue.7, pp.822-835, 2018.
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics, Clin Cancer Res Off J Am Assoc Cancer Res, vol.24, issue.14, pp.3292-3298, 2018. ,
Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma, Oncotarget, vol.8, issue.23, pp.38056-38060, 2017. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.2, pp.123-135, 2015. ,
Big Data and medicine: a big deal, J Intern Med, vol.283, issue.5, pp.418-429, 2018. ,
Machine learning models in breast cancer survival prediction. Technol Health Care Off J, Eur Soc Eng Med, vol.24, issue.1, pp.31-42, 2016. ,
Lung Cancer Survival Prediction via Machine Learning Regression, Classification, and Statistical Techniques, Proc IEEE Int Symp Signal Process Inf Technol IEEE Int Symp Signal Process Inf Technol, vol.2018, pp.632-637, 2018. ,
A radiomics approach to assess tumourinfiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, vol.19, issue.9, pp.1180-1191, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01958243